Literature DB >> 11452162

In vivo survival of apheresis RBCs, frozen with 40-percent (wt/vol) glycerol, deglycerolized in the ACP 215, and stored at 4 degrees C in AS-3 for up to 21 days.

C R Valeri1, G Ragno, L Pivacek, E M O'Neill.   

Abstract

BACKGROUND: The FDA has approved the storage of frozen RBCs at -80 degrees C for 10 years and the postwash storage at 4 degrees C for no more than 24 hours. The 4 degrees C postwash storage period is limited to 24 hours, because the current deglycerolization systems are functionally open systems. STUDY DESIGN AND METHODS: Two units of RBCs were collected from each of 13 healthy male volunteers. The RBCs were collected in CP2D by the FDA-approved protocol for an automated apheresis device (MCS, LN8150, Haemonetics) and were stored at 4 degrees C in AS-3 for 6 days. Using a single disposable glycerolization set in an automated, functionally closed system (ACP 215, Haemonetics) each unit was transferred to a 1000-mL PVC plastic bag and glycerolized to a concentration of 40-percent (wt/vol) glycerol and frozen at -80 degrees C. A single disposable deglycerolization set in the ACP 215 was used to deglycerolize the 2 units from the same donor. The deglycerolized RBCs were stored at 4 degrees C in AS-3 for as long as 21 days.
RESULTS: The mean +/- SD freeze-thaw-wash recovery value was 89.4 +/- 3 percent. The residual hemolysis in the RBCs stored at 4 degrees C in AS-3 for 21 days after deglycerolization was 0.9 +/- 0.2 percent, and the units were negative for both aerobic and anaerobic bacteria. The mean Nageotte WBC count was 9 x 10(6) per unit. When the deglycerolized RBCs were given as an autologous transfusion after storage at 4 degrees C in AS-3 for the 7- to 18-day period, the mean +/- SD 24-hour posttransfusion survival was 77 +/- 7 percent, and the index of therapeutic effectiveness was 69 +/- 8 percent.
CONCLUSION: Two units of human RBCs collected from a single donor by apheresis in the MCS using an LN8150 set can be glycerolized sequentially with a single disposable set and deglycerolized sequentially with another single disposable set in the ACP 215. The previously frozen RBCs stored in AS-3 for 7 to 18 days at 4 degrees C had acceptable hemolysis and an acceptable mean 24-hour posttransfusion survival value and index of therapeutic effectiveness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452162     DOI: 10.1046/j.1537-2995.2001.41070928.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  From Development to Implementation: Adjusting the Hematocrit of Deglycerolized Red Cell Concentrates to Meet Regulatory Standards.

Authors:  Tracey Turner; Adele Hansen; Jayme Kurach; Jason P Acker
Journal:  Transfus Med Hemother       Date:  2016-11-04       Impact factor: 3.747

2.  In vitro parameters of cryopreserved leucodepleted and non-leucodepleted red blood cells collected by apheresis or from whole blood and stored in AS-3 for 21 days after thawing.

Authors:  Miloš Bohoněk; Marek Petráš; Ivo Turek; Jaroslava Urbanová; Tomáš Hrádek; Věra Staropražská; Jitka Koštířová; Dana Horčičková; Simona Duchková
Journal:  Blood Transfus       Date:  2013-02-06       Impact factor: 3.443

3.  Implications of variability in cell membrane permeability for design of methods to remove glycerol from frozen-thawed erythrocytes.

Authors:  John M Lahmann; Cynthia Cruz Sanchez; James D Benson; Jason P Acker; Adam Z Higgins
Journal:  Cryobiology       Date:  2020-01-11       Impact factor: 2.487

4.  Red blood cell phenotype fidelity following glycerol cryopreservation optimized for research purposes.

Authors:  Stephen C Rogers; Laura B Dosier; Timothy J McMahon; Hongmei Zhu; David Timm; Hengtao Zhang; Joseph Herbert; Jacqueline Atallah; Gregory M Palmer; Asa Cook; Melanie Ernst; Jaya Prakash; Mark Terng; Parhom Towfighi; Reid Doctor; Ahmed Said; Matthew S Joens; James A J Fitzpatrick; Gabi Hanna; Xue Lin; Julie A Reisz; Travis Nemkov; Angelo D'Alessandro; Allan Doctor
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

5.  Measuring Post-transfusion Recovery and Survival of Red Blood Cells: Strengths and Weaknesses of Chromium-51 Labeling and Alternative Methods.

Authors:  Camille Roussel; Pierre A Buffet; Pascal Amireault
Journal:  Front Med (Lausanne)       Date:  2018-05-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.